- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
- Drug
- Lead sponsor
- R-Pharm International, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 4,565
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes, Liver Disease
- Interventions
- Behavioral Treatment
- Device
- Lead sponsor
- SIPPA Solutions INC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jamaica, New York
- Conditions
- Neurofibromatoses
- Interventions
- Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
- Drug
- Lead sponsor
- Harry T Whelan, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Mouth Abnormalities, Cleft Palate, Birth Defect
- Interventions
- Ropivacaine, Sham Comparator
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 3 Months to 5 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- PF-06939926
- Genetic
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Opioid-Induced Constipation
- Interventions
- NKTR-118, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 81
- States / cities
- Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more
- Conditions
- SCI - Spinal Cord Injury
- Interventions
- Preload condition, Ad-libitum control condition
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Low Back Pain, Pregnancy
- Interventions
- Osteopathic Manipulative Treatment, Placebo Ultrasound
- Other
- Lead sponsor
- University of North Texas Health Science Center
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Schizophrenia
- Interventions
- AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • Rockville, Maryland
- Conditions
- Nutritional Status
- Interventions
- GSK1325756
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Second Hand Tobacco Smoke
- Interventions
- Smoke-free homes intervention
- Behavioral
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Psoriasis
- Interventions
- Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
- Drug
- Lead sponsor
- Sirtris, a GSK Company
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- PF-07081532, Placebo, Clopidogrel
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Anaheim, California • South Miami, Florida
- Conditions
- Dermatitis, Atopic
- Interventions
- Educational handbook
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 30 Days to 16 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- RSV Illness in ≤12 Months of Participants
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Long Beach, California • Orange, California + 23 more
- Conditions
- Overactive Bladder
- Interventions
- Tolterodine ER, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Head Lice
- Interventions
- Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 905 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Dietary Supplement
- Interventions
- Whey Protein Micro Gel, Water without Whey Protein.
- Dietary Supplement · Other
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Methamphetamine Abuse
- Interventions
- normal saline, ch-mAb7f9
- Biological
- Lead sponsor
- InterveXion Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Cognitive Processing Therapy (CPT), Accelerated Resolution Therapy (ART)
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Interventions
- Belimumab, Placebo for Belimumab, Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
- Conditions
- Peyronie's Disease
- Interventions
- CCH administration, Control - Crossover to CCH, RestoreX
- Drug · Device
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's Disease
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orem, Utah